Abstract
The high mortality rate and lack of effective therapies make lung cancer an ideal target for novel therapeutic agents. The present study was designed to implement a novel chemical synthesis pathway and to determine the biological activities of synthetic makaluvamine analogs in human lung cancer. Seventeen compounds were synthesized and purified, and their chemical structures were elucidated on the basis of physicochemical constants and NMR spectra. Their in vitro activity was determined in human lung cancer cell lines. Based on initial screens, compound Ic was found to be the most potent, and was therefore used as a model for further studies in lung cancer cells. Ic induced both apoptosis and S-phase cell cycle arrest. Furthermore, it activated p53 and induced cleavage of PARP and caspases 8 and 9. Our preclinical data indicate that the makaluvamine analogs are potential therapeutic agents against lung cancer, providing a basis for further development of Ic (and perhaps other analogs) as a novel anti-cancer agent.
Keywords: Makaluvamine, marine alkaloid, lung cancer, apoptosis
Medicinal Chemistry
Title: Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-o ne Alkaloid Analogs
Volume: 5 Issue: 3
Author(s): Dwayaja H. Nadkarni, Feng Wang, Wei Wang, Elizabeth R. Rayburn, Scharri J. Ezell, Srinivasan Murugesan, Sadanandan E. Velu and Ruiwen Zhang
Affiliation:
Keywords: Makaluvamine, marine alkaloid, lung cancer, apoptosis
Abstract: The high mortality rate and lack of effective therapies make lung cancer an ideal target for novel therapeutic agents. The present study was designed to implement a novel chemical synthesis pathway and to determine the biological activities of synthetic makaluvamine analogs in human lung cancer. Seventeen compounds were synthesized and purified, and their chemical structures were elucidated on the basis of physicochemical constants and NMR spectra. Their in vitro activity was determined in human lung cancer cell lines. Based on initial screens, compound Ic was found to be the most potent, and was therefore used as a model for further studies in lung cancer cells. Ic induced both apoptosis and S-phase cell cycle arrest. Furthermore, it activated p53 and induced cleavage of PARP and caspases 8 and 9. Our preclinical data indicate that the makaluvamine analogs are potential therapeutic agents against lung cancer, providing a basis for further development of Ic (and perhaps other analogs) as a novel anti-cancer agent.
Export Options
About this article
Cite this article as:
Nadkarni H. Dwayaja, Wang Feng, Wang Wei, Rayburn R. Elizabeth, Ezell J. Scharri, Murugesan Srinivasan, Velu E. Sadanandan and Zhang Ruiwen, Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8- Tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-o ne Alkaloid Analogs, Medicinal Chemistry 2009; 5 (3) . https://dx.doi.org/10.2174/157340609788185873
DOI https://dx.doi.org/10.2174/157340609788185873 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Influence of PEG Molecular Weight on the Drug Release and In vitro Cytotoxicity of Single-Walled Carbon Nanotubes-PEG-Gemcitabine Conjugates
Current Drug Delivery MicroRNA Expression in Coronary Artery Disease
MicroRNA Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer
Current Cancer Drug Targets Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients
Current Drug Targets Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis
Anti-Cancer Agents in Medicinal Chemistry Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyltransferase Type-I (GGTase-I) Inhibitors by Molecular Modeling
Combinatorial Chemistry & High Throughput Screening Finding Drug Targets Through Analysis of the Platelet Transcriptome
Current Pharmaceutical Design New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Influence of New Synthetic Xanthones on the Proliferation and Migration Potential of Cancer Cell Lines In Vitro
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic:Utilizing Chinese Medicines to Improve Cancer Therapy - Fiction or Reality?(Guest Editors: Ying Huang and Moses Sing Sum Chow)]
Current Drug Discovery Technologies Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design